Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis

Background: Postoperative proliferative vitreoretinopathy (PVR) remains a dilemma for retinal surgeons. We performed a literature search and meta-analyses to figure out whether combined 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) treatment were effective in improving the primary su...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chen Chen, Peng Chen, Xia Liu, Hua Li
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/9902e0230e4c49ed82269c5f7cd41113
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9902e0230e4c49ed82269c5f7cd41113
record_format dspace
spelling oai:doaj.org-article:9902e0230e4c49ed82269c5f7cd411132021-12-01T18:28:24ZCombined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis2296-858X10.3389/fmed.2021.790460https://doaj.org/article/9902e0230e4c49ed82269c5f7cd411132021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.790460/fullhttps://doaj.org/toc/2296-858XBackground: Postoperative proliferative vitreoretinopathy (PVR) remains a dilemma for retinal surgeons. We performed a literature search and meta-analyses to figure out whether combined 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) treatment were effective in improving the primary success of vitrectomy and preventing postoperative PVR occurrence in patients with retinal detachment (RD).Methods: Databases including PubMed, Embase, the Cochrane library, and China National Knowledge Infrastructure (CNKI) were searched from inception to May 2021. Comparative studies approaching the effects of combined 5-FU and LMWH on postoperative PVR were included. Quality assessment was performed using RoB 2 and ROBINS-I tool. Study data were pooled using Review manager 5.4.1. The main outcomes were: the primary success of vitrectomy at 6 months and the postoperative PVR occurrence. The additional outcomes were: number of patients who underwent vitreoretinal reoperations and the number of vitreoretinal reoperations due to postoperative PVR. Subgroup analyses and sensitivity analyses were also performed.Results: Six clinical trials with a total of 1,208 participants were included. We found that combined 5-FU and LMWH infusion did not improve the primary success of vitrectomy at 6 months (RR = 1.00, 95% CI = 0.95, 1.07, P = 0.89, I2 = 50%). Also, the conjunct therapy had no effect on reducing the number of patients who underwent vitreoretinal reoperations (RR = 1.00, 95% CI = 0.78, 1.28, P = 1.00, I2 = 42%). The overall effect of the treatment on preventing postoperative PVR was negative. However, in patients with PVR grade C (PVRC) before intervention, the 5-FU and LMWH treatment significantly reduced PVR occurrence. Visual acuity was not different between the treatment and control groups. Nevertheless, in one RCT, a significant reduction of VA was observed in the treatment group in macular-sparing patients with RD. No complications were attributed to the conjunct therapy.Conclusions: The combined 5-FU and LMWH treatment neither improved the primary success of vitrectomy at 6 months nor decreased number of patients who underwent vitreoretinal reoperations. Thus, the treatment should not be routinely used in vitrectomy for patients with RD. However, the treatment proved beneficial in reducing postoperative PVR in patients with PVRC before intervention. More high-quality clinical trials are needed to confirm the results.Systematic Review Registration:https://inplasy.com/inplasy-2021-8-0117/, identifier: INPLASY202180117.Chen ChenChen ChenChen ChenPeng ChenXia LiuHua LiHua LiHua LiFrontiers Media S.A.articleproliferative vitreoretinopathyretinal detachmentvitrectomy5-fluorouracillow molecular weight heparinmeta-analysisMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution DOAJ
collection DOAJ
language EN
topic proliferative vitreoretinopathy
retinal detachment
vitrectomy
5-fluorouracil
low molecular weight heparin
meta-analysis
Medicine (General)
R5-920
spellingShingle proliferative vitreoretinopathy
retinal detachment
vitrectomy
5-fluorouracil
low molecular weight heparin
meta-analysis
Medicine (General)
R5-920
Chen Chen
Chen Chen
Chen Chen
Peng Chen
Xia Liu
Hua Li
Hua Li
Hua Li
Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis
description Background: Postoperative proliferative vitreoretinopathy (PVR) remains a dilemma for retinal surgeons. We performed a literature search and meta-analyses to figure out whether combined 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) treatment were effective in improving the primary success of vitrectomy and preventing postoperative PVR occurrence in patients with retinal detachment (RD).Methods: Databases including PubMed, Embase, the Cochrane library, and China National Knowledge Infrastructure (CNKI) were searched from inception to May 2021. Comparative studies approaching the effects of combined 5-FU and LMWH on postoperative PVR were included. Quality assessment was performed using RoB 2 and ROBINS-I tool. Study data were pooled using Review manager 5.4.1. The main outcomes were: the primary success of vitrectomy at 6 months and the postoperative PVR occurrence. The additional outcomes were: number of patients who underwent vitreoretinal reoperations and the number of vitreoretinal reoperations due to postoperative PVR. Subgroup analyses and sensitivity analyses were also performed.Results: Six clinical trials with a total of 1,208 participants were included. We found that combined 5-FU and LMWH infusion did not improve the primary success of vitrectomy at 6 months (RR = 1.00, 95% CI = 0.95, 1.07, P = 0.89, I2 = 50%). Also, the conjunct therapy had no effect on reducing the number of patients who underwent vitreoretinal reoperations (RR = 1.00, 95% CI = 0.78, 1.28, P = 1.00, I2 = 42%). The overall effect of the treatment on preventing postoperative PVR was negative. However, in patients with PVR grade C (PVRC) before intervention, the 5-FU and LMWH treatment significantly reduced PVR occurrence. Visual acuity was not different between the treatment and control groups. Nevertheless, in one RCT, a significant reduction of VA was observed in the treatment group in macular-sparing patients with RD. No complications were attributed to the conjunct therapy.Conclusions: The combined 5-FU and LMWH treatment neither improved the primary success of vitrectomy at 6 months nor decreased number of patients who underwent vitreoretinal reoperations. Thus, the treatment should not be routinely used in vitrectomy for patients with RD. However, the treatment proved beneficial in reducing postoperative PVR in patients with PVRC before intervention. More high-quality clinical trials are needed to confirm the results.Systematic Review Registration:https://inplasy.com/inplasy-2021-8-0117/, identifier: INPLASY202180117.
format article
author Chen Chen
Chen Chen
Chen Chen
Peng Chen
Xia Liu
Hua Li
Hua Li
Hua Li
author_facet Chen Chen
Chen Chen
Chen Chen
Peng Chen
Xia Liu
Hua Li
Hua Li
Hua Li
author_sort Chen Chen
title Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis
title_short Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis
title_full Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis
title_fullStr Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis
title_full_unstemmed Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis
title_sort combined 5-fluorouracil and low molecular weight heparin for the prevention of postoperative proliferative vitreoretinopathy in patients with retinal detachment: a meta-analysis
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/9902e0230e4c49ed82269c5f7cd41113
work_keys_str_mv AT chenchen combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
AT chenchen combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
AT chenchen combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
AT pengchen combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
AT xialiu combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
AT huali combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
AT huali combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
AT huali combined5fluorouracilandlowmolecularweightheparinforthepreventionofpostoperativeproliferativevitreoretinopathyinpatientswithretinaldetachmentametaanalysis
_version_ 1718404707943186432